International Journal of Allergy

International Journal of Allergy

International Journal of Allergy – About

Open Access & Peer-Reviewed

Submit Manuscript
International Journal of Allergy

A peer-reviewed, open-access journal for immunological research into allergic disease and hypersensitivity — from mast cell and IgE biology to allergen structure and immune biomarkers.

Open access · CC BY 4.0 · Single-blind peer review · First decision in about 21 days

What IJA is

The International Journal of Allergy (IJA) publishes original research, reviews, and short communications on the immunological mechanisms of allergy and hypersensitivity. It is written for immunologists, allergists, and translational scientists studying how the immune system drives allergic inflammation at the cellular, antibody, and molecular level.

IJA is deliberately mechanistic. It prioritises work that explains how hypersensitivity arises — immune-cell behaviour, antibody responses, receptor and cytokine signalling, allergen immunology, and biomarkers — rather than clinical management or drug-efficacy trials. Every accepted article is published open access under CC BY 4.0 and receives a Crossref DOI.

Journal at a glance

Access model
Open access, immediate
Licence
CC BY 4.0 · authors retain copyright
Peer review
Single-blind · two or more independent reviewers
First decision
About 21 days from submission
Article-processing charge
US$1,200 (US$540 for students) · on acceptance only
Article identifier
A Crossref DOI on every article
Discoverability
Google Scholar and OpenAlex
Editorial board
9 members across 9 countries
Publication ethics
COPE-aligned

What IJA publishes

IJA maintains a disciplined focus on the immunological mechanisms of allergy — the molecular, cellular, and systemic processes that produce hypersensitivity.

Immune cell biology

Mast cell degranulation, basophil and eosinophil function, Th1/Th2 balance, regulatory T cells, and dendritic-cell antigen presentation.

Antibody & immunoglobulin biology

IgE synthesis and regulation, IgG4 responses, B-cell activation, and humoral immunity in hypersensitivity.

Hypersensitivity mechanisms

Type I–IV pathways, complement activation, immune-complex formation, and cytokine-driven inflammation.

Immunological signalling

FcεRI receptor signalling, IL-4/IL-5/IL-13 networks, chemokine-mediated recruitment, and JAK–STAT pathways.

Allergen immunology

Allergen structure and immunogenicity, epitope mapping, cross-reactivity, and allergen processing and presentation.

Immune biomarkers

Discovery and validation of biomarkers for sensitisation and disease mechanism, and immune-profiling methods.

In scope

  • Mechanistic studies of immune-cell behaviour and antibody responses
  • Receptor, cytokine, and signalling pathway analysis
  • Allergen biochemistry and immunological models
  • Biomarker discovery and immunogenetics

Out of scope

  • Clinical case reports, treatment protocols, and diagnostic guidelines
  • Patient-management strategies and immunotherapy-administration studies
  • Epidemiological surveys and public-health studies
  • Non-immunological disease mechanisms

See the full Aims & Scope →

Editorial board

IJA is guided by an international editorial board of nine researchers in allergy and clinical immunology, spanning nine countries. Board members assess manuscripts within their areas of expertise and uphold the journal’s editorial standards.

Danilo Di BonaAllergology & Clinical Immunology, University of Bari Aldo Moro, Italy
Elsayed ElagamyProfessor of Immunology, Qassim University, Saudi Arabia
Anne M. DittoNorthwestern Memorial Hospital, United States
Bobette MatulongaInserm, Paris, France

Meet the full editorial board →

How publication works

  1. 1SubmitUpload your manuscript through the online submission system.
  2. 2Editorial screeningThe editorial office checks scope fit and completeness within 2–3 business days.
  3. 3Peer reviewSingle-blind review by two or more independent experts.
  4. 4DecisionA first editorial decision within about 21 days of submission.
  5. 5RevisionPoint-by-point response; revised manuscripts are re-assessed promptly.
  6. 6PublicationAccepted articles are copyedited, assigned a Crossref DOI, and published open access.

Free to submit and to be reviewed — the article-processing charge applies only after acceptance.

What every IJA article receives

  • A registered Crossref DOI for every article
  • Immediate open access under CC BY 4.0 — you keep the copyright
  • Discoverability through Google Scholar and OpenAlex
  • Single-blind peer review by two or more independent experts
  • Editorial handling aligned with COPE guidelines
  • Professional copyediting before publication

Ethics & research integrity

IJA follows the Committee on Publication Ethics (COPE) principles and international reporting standards:

  • Human-subjects research requires ethics-committee approval, informed consent, and adherence to the Declaration of Helsinki.
  • Animal research requires IACUC (or equivalent) approval and ARRIVE-compliant reporting.
  • All authors disclose funding sources and competing interests.
  • Data must be original and available; image manipulation is prohibited.
  • Authorship follows ICMJE criteria, and any use of AI tools must be disclosed.

Article types

Original Research

Novel immunological investigations using experimental, cellular, molecular, or model systems.

Review Articles

Critical syntheses of a specific immunological mechanism that identify clear knowledge gaps.

Short Communications

Concise reports of preliminary findings, new methods, or hypothesis-generating observations.

Prepare your manuscript: Instructions for Authors →

Submit your allergy immunology research

IJA welcomes mechanistically rigorous studies that explain how the immune system drives allergic inflammation. There is no charge to submit or to be reviewed; the article-processing charge applies only on acceptance.

Editorial office: [email protected] — for questions about scope fit, submission, or editorial policies.